GMP: Good Manufacturing Practice: API Manufacturing
Following initial processing of herbal product, active ingredients are extracted under GMP conditions to produce an oil with approximately 50% cannabinoids. This can then be further refined to remove impurities and concentrate cannabinoids.
The Active Pharmaceutical Ingredients are standardised, GMP ingredients that can then be sold as wholesale products, or further formulated into final product forms such as tinctures, tablets, capsules and topical products.
The resultant APIs can be exported and sold to manufacturers, or formulated into final product forms. These APIs are the commodities of the cannabis industry, and are often traded in the 100s, thousands or 10,000s of kg as part of supply and offtake agreements.
API Manufacture and Distribution are governed by specialised areas of GxP.
Cannabis Active Pharmaceutical Ingredients (APIs)
- Granulated Standardised Dried Herbal Cannabis (10-20% cannabinoids)
- Raw Cannabis Oil (40-50% cannabinoids)
- Winterised Cannabis Oil (45-55% cannabinoids)
- Distillate (80 to 85% cannabinoids)
- Double Distillate (90 to 98% cannabinoids)
- Isolated cannabinoids (99.0% to 99.9% cannabinoids)
Medical Cannabis GxP: Good Practices for Medical Cannabis
- GAP: Good Agricultural Practice: Propagation and Cultivation
- GMP: Good Manufacturing Practice: Processing Herbal Product into Medicines
- GDP: Good Distribution Practice: Sales, Brokerage and Distribution
- GCP: Good Clinical Practice: Prescribing and Clinical Trials
- GLP: Good Laboratory Practice: Clinical Testing and Analytic Testing (Also covered by ISO)
- Rhizo Sciences Quality Statement for Medical Cannabis